Compositions and methods for treatment of type 1 diabetes

A composition, technology of BHT-3021, applied in botany equipment and methods, biochemical equipment and methods, chemical instruments and methods, etc.

Pending Publication Date: 2016-03-16
TOLERION
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these methods have been successful,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treatment of type 1 diabetes
  • Compositions and methods for treatment of type 1 diabetes
  • Compositions and methods for treatment of type 1 diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0073] In type 1 diabetes, there is a strong inflammatory response that destroys islets in the pancreas, the site of insulin production and release. In type 1 diabetes (T1D), proinsulin is a major target of the adaptive immune response. The present invention provides an engineered DNA plasmid (BHT-3021) encoding proinsulin that preserves beta cell function in T1D patients by reducing insulin-specific CD8 T cells. We studied 80 subjects over the age of 18 who had been diagnosed with TlD within the past five years. Subjects were randomized 2:1 to receive intramuscular injections of BHT3021 or BHT-placebo once weekly for 12 weeks, followed by blinded monitoring of safety and immune responses. Four dose levels of BHT-3021 were evaluated: 0.3 mg, 1.0 mg, 3.0 mg, and 6.0 mg. C-peptide was used as an efficacy measure and a safety measure for the investigation. Islet-specific CD8 T cell frequencies were assessed using multimers of HLA class I monomers loaded with pancreas-derived p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides compositions and methods for treating insulin-dependent diabetes mellitus in a subject comprising administration of a self-vector encoding and expressing human proinsulin.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application No. 61 / 818,671, filed May 2, 2013. field of invention [0003] The present invention relates to compositions and methods for treating insulin-dependent diabetes in a subject. Background of the invention [0004] One of the hallmarks of type 1 diabetes (T1D) is an inflammatory response that ultimately destroys pancreatic beta cells (a process known as insulitis). CD8 T cells against a variety of islet antigens including preproinsulin (PPI), glutamate decarboxylase (GAD), tyrosine phosphatase-like have been detected in blood and islets of individuals with T1D. Insulinoma antigen (IA2, also known as ICA512), zinc transporter ZnT8, and islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) (1-3). Therefore, attempts have been made to delay T1D with antigen-specific therapies, including parenteral and nasal administration of insulin (4-6...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/00C12N15/63A61K48/00A61K38/28
CPCA61K48/005C12N15/85C12N2800/101C12N2800/107C12N2800/24C07K14/62A61K2039/53A61K2039/55561A61K39/0008A61K2039/572A61K2039/575A61K2039/577A61P3/10A61K48/00A61K2039/54
Inventor 巴特·O·勒普威廉·H·罗宾森保罗·乌茨海德基·葛元劳伦斯·斯坦曼
Owner TOLERION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap